# OnCo record rovalpituzumab-tesirine (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/rovalpituzumab-tesirine/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "rovalpituzumab-tesirine" ;
  schema:name "Rovalpituzumab tesirine"@en ;
  schema:description "Rovalpituzumab tesirine (Rova-T) was the first drug against DLL3 in small-cell lung cancer. AbbVie bought it for $5.8B and abandoned it after two failed phase 3 trials. The target later worked with a different weapon."@en ;
  schema:url <https://onco.cc/drugs/rovalpituzumab-tesirine/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Rovalpituzumab_tesirine> ;
  owl:sameAs <http://www.wikidata.org/entity/Q30314129> ;
  schema:citation <https://www.jto.org/article/S1556-0864(21)02264-5/fulltext> ;
  onco:status "withdrawn" ;
  onco:tag "failure", "lesson:wrong-drug" ;
  onco:modality "ADC" ;
  onco:cancers <https://onco.cc/cancers/sclc/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/dll3/> ;
  onco:drugs <https://onco.cc/drugs/tarlatamab/> ;
  onco:companies <https://onco.cc/companies/abbvie/> ;
  onco:trials <https://onco.cc/trials/nct03033511/>, <https://onco.cc/trials/nct03061812/>, <https://onco.cc/trials/nct02674568/> .